Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Accenture
Argus Health
Citi
Fuji
Merck
Express Scripts
AstraZeneca
Baxter

Generated: June 20, 2018

DrugPatentWatch Database Preview

Pasireotide pamoate - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for pasireotide pamoate and what is the scope of pasireotide pamoate freedom to operate?

Pasireotide pamoate
is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pasireotide pamoate has one hundred and twenty-three patent family members in fifty countries.

One supplier is listed for this compound.
Summary for pasireotide pamoate
International Patents:123
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 3
Clinical Trials: 81
DailyMed Link:pasireotide pamoate at DailyMed
Synonyms for pasireotide pamoate
04F55A7UZ3
396091-79-5
CHEMBL3545188
Cyclo((2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-L-prolyl), 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1)
Pasireotide embonate
Signifor LAR
SOM-230 pamoate
SOM230 pamoate
UNII-04F55A7UZ3

US Patents and Regulatory Information for pasireotide pamoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-002 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for pasireotide pamoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-002 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-003 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for pasireotide pamoate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,625 Somatostatin analogues ➤ Try a Free Trial
9,035,021 Somatostatin analogues ➤ Try a Free Trial
8,188,037 Microparticles comprising somatostatin analogues ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for pasireotide pamoate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90022-1 Sweden ➤ Try a Free Trial PRODUCT NAME: PASIREOTID; REG. NO/DATE: EU/1/12/753/001 20120424
2012 00024 Denmark ➤ Try a Free Trial PRODUCT NAME: PASIREOTID OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753/001-012 20120424
024 Luxembourg ➤ Try a Free Trial 92024, EXPIRES: 20260730
2015 00026 Denmark ➤ Try a Free Trial PRODUCT NAME: PASIREOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET HVILKET SOM HELST HYDRAT DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753, C(2014)8916 20141121
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
McKinsey
Boehringer Ingelheim
Harvard Business School
Accenture
Colorcon
QuintilesIMS
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.